Goodflo 150mg Capsule contains Dabigatran Etexilate, an oral anticoagulant indicated for the prevention and treatment of thromboembolic disorders. Dabigatran Etexilate is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin, thereby reducing clot formation. It is primarily prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Goodflo 150mg Capsule offers a fixed-dose regimen without the need for routine coagulation monitoring, providing a convenient alternative to vitamin K antagonists. The medication is absorbed as a prodrug and rapidly converted to its active form, with peak plasma concentrations achieved within 1-2 hours post-administration. It is essential to adhere to prescribed dosing schedules and to inform healthcare providers of any concomitant medications to avoid potential drug interactions, particularly with P-glycoprotein inhibitors or inducers. Caution is advised in patients with renal impairment, as dose adjustments may be necessary. Common adverse effects include bleeding complications, dyspepsia, and gastrointestinal discomfort. Goodflo should be used under medical supervision, with regular evaluation of renal function and bleeding risk to ensure safe and effective therapy.